1. "Lymphoma"
Formats
  1. Meeting Abstract (1340)
  2. Journal Article (1048)
  3. Book Section (63)
  4. Review (63)
  5. Editorial (37)
  6. Research Letter (35)
  7. Guidelines (18)
  8. Conference Paper (15)
  9. Correspondence (11)
  10. Miscellaneous (5)
  11. Book Whole (4)
Groups
  1. Center for Hematologic Malignancies (2639)
  2. Department of Medicine (2639)
  3. Hematologic Malignancies, Division of (2639)
  4. Lymphoma (2639)
  5. Population Sciences Research Program (720)
  6. Survivorship Research (633)

More Groups

People
  1. Andrew Zelenetz (767)
  2. Steven Horwitz (645)
  3. Maria Palomba (415)
  4. David Straus (356)
  5. Ariela Noy (351)
  6. Alison Moskowitz (339)

More People

Years
  1. 2025 (28)
  2. 2024 (100)
  3. 2023 (180)
  4. 2022 (170)
  5. 2021 (171)
  6. 2020 (170)

More Years

Publications
  1. Blood (833)
  2. Journal of Clinical Oncology (274)
  3. Hematological Oncology (110)
  4. Leukemia and Lymphoma (81)
  5. British Journal of Haematology (79)
  6. Haematologica (71)

More Publications

Publishers
  1. American Society of Hematology (898)
  2. American Society of Clinical Oncology (290)
  3. Elsevier Inc. (187)
  4. Wiley Blackwell (173)
  5. John Wiley & Sons (95)
  6. Nature Publishing Group (92)

More Publishers

Results (2639)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Evaluation of the m7-FLIPI in patients with follicular lymphoma: FOXO1 mutational status may be a predictive marker of early progression and long-term outcome
    Meeting Abstract

    Bantilan, K. S.; Zelenetz, A. D.
    Blood (2023)

    Fulltext@MSK | Save
  • From widespread to tailored antifungal prophylaxis in lymphoma patients treated with CD19 CAR T- cell therapy: Less is better
    Meeting Abstract

    Melica, G.; Luna De Abia, A.; Corona, M.; Fein, J.; Dahi, P. B.; Giralt, S. A.; Landego, I.; Lin, R. J.; Palomba, M. L.; Parascondola, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Genetic alterations of follicular lymphoma can predict response to very low dose radiotherapy
    Meeting Abstract

    Wijetunga, N. A.; Lebow, E.; Chan, A.; Fregonese, B.; Seshan, V.; Hajj, C.; Cederquist, G.; Hubbeling, H.; Ma, J.; Sarkar, R. R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase 2 study of minimal residual disease (MRD)-adapted front line venetoclax and obinutuzumab in fit patients with chronic lymphocytic leukemia (CLL): Effect of obinutuzumab on tumor lysis syndrome (TLS) risk and safety of outpatient venetoclax dose escalation
    Meeting Abstract

    Roeker, L. E.; Zelenetz, A. D.; Park, J. H.; Derkach, A.; Geyer, M. B.; Islam, P.; Falchi, L.; Palomba, M. L.; Kumar, A.; Salles, G.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of response to systemic bridging therapy on clinical outcomes and cytokine profiles in patients receiving CD19-CAR T-cell therapy for B-cell lymphoma
    Meeting Abstract

    Wills, B.; Shouval, R.; Flynn, J. R.; Devlin, S. M.; Parascondola, A.; Saldia, A.; Imber, B. S.; Tomas, A. A.; Landego, I.; Lin, R. J.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Evaluation of the impact of tocilizumab use in recipients of CAR T cells for non-Hodgkin lymphoma
    Meeting Abstract

    Cassanello, G.; Luttwak, E.; Devlin, S. M.; Luna De Abia, A.; Corona, M.; Landego, I.; Parascondola, A.; Saldia, A.; Tomas, A. A.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase 1b multi-center study of the FLT3 inhibitor gilteritinib in combination with the IDH1 inhibitor ivosidenib or the IDH2 inhibitor enasidenib for patients with relapsed or refractory acute myeloid leukemia who have co-occurring FLT3/IDH1 or FLT3/IDH2 mutations
    Meeting Abstract

    Stein, E. M.; Derkach, A.; Melamed, G.; Block, A.; Kim, J.; Georgieva, G.; Thompson, V.; Levine, R. L.; Intlekofer, A. M.; Abdel-Wahab, O.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Responses and outcomes after second-line therapy in transplant-eligible patients with DLBCL relapse over 1 year after first-line therapy
    Meeting Abstract

    Qualls, D. A.; Shah, G. L.; Shouval, R.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Pilot study of longitudinal geriatric assessment and neurocognitive evaluation in CAR T-cell therapy for older patients with relapsed refractory, large B-cell lymphoma
    Meeting Abstract

    Lin, R. J.; Kim, S. J.; Correa, D.; Elko, T. A.; Lobaugh, S.; Baser, R.; Koch, A.; Hanley, D. M.; Palomba, M. L.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • CNS radiotherapy as bridging prior to CAR T-cell therapy for non-Hodgkin B-cell lymphoma
    Meeting Abstract

    Cederquist, G.; Schefflein, J.; Devlin, S. M.; Hubbeling, H.; Tringale, K.; Shah, G. L.; Tomas, A. A.; Shouval, R.; Hajj, C.; Fregonese, B.; more...
    Blood (2023)

    Fulltext@MSK | Save